" /> Degarelix - CISMeF





Preferred Label : Degarelix;

NCIt synonyms : N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide;

NCIt definition : A long-acting, synthetic peptide with gonadotrophin-releasing hormone (GnRH) antagonistic properties. Degarelix targets and blocks GnRH receptors located on the surfaces of gonadotroph cells in the anterior pituitary, thereby reducing secretion of luteinizing hormone (LH) by pituitary gonadotroph cells and so decreasing testosterone production by interstitial (Leydig) cells in the testes.;

Alternative definition : NCI-GLOSS: A drug that is used to treat advanced prostate cancer and is also being studied in the treatment of benign prostatic hyperplasia. Degarelix binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland. This causes the body to stop making testosterone, which prostate cancer needs to grow. Degarelix is a type of GnRH antagonist.;

UNII : SX0XJI3A11;

InChIKey : MEUCPCLKGZSHTA-XYAYPHGZSA-N;

CAS number : 214766-78-6;

Drug name : Firmagon;

Molecule name : FE 200486; ASP 3550; FE-200486; ASP-3550;

Chemical formula : C82H103ClN18O16;

Codes from synonyms : CDR0000631495; 151;

Détails


Position du mot-clé dans l'(les) arborescence(s) : arborescence

Vous pouvez consulter :


Nous contacter.
27/07/2025


[Accueil] [Haut de page]

© CHU de Rouen. Toute utilisation partielle ou totale de ce document doit mentionner la source.